Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

MDR-TB

National Institute for Health and Care Excellence NICE logo

NICE gives final backing to drugs from Bayer, GSK and Otsuka

Eylea, Revolade and Abilify all recommended for NHS use

- PMLiVE

Non-amyloid therapies emerging for Alzheimer’s at AAIC

AAIC meeting hears new clinical data from Lundbeck, Baxter, Chiesi and Takeda

- PMLiVE

New formulations of Pralia and Enbrel head list of new drugs in Japan

Regulator backs medicines from Pfizer, Takeda, Daiichi Sankyo, Astellas, Zeria and otsuka

- PMLiVE

Pharma companies partner with Japanese government

GHIT Fund will support development of medicines for infectious diseases in developing countries

- PMLiVE

Otsuka files new TB candidate in Japan as shortages worsen

Delamanid shows promise in multi-drug resistant TB but supplies of rifampin are low

- PMLiVE

Otsuka licenses Lundbeck’s Alzheimer’s drug in $825m deal

Lu AE58054 is in phase III development as add-on to donepezil

- PMLiVE

Otsuka’s Pletal has use restricted in Europe

EMA recommends drug only be used in limited group of patients with blood supply disorder

- PMLiVE

WHO claims $1.3bn annual funding gap for tuberculosis research

Says action needs to be taken now to halt spread of multi-drug resistant TB

- PMLiVE

Otsuka and Lundbeck extend CNS collaboration

Follows US approval of depot antipsychotic Abilify Maintena

- PMLiVE

Depot Abilify approval in US buoys Lundbeck and Otsuka

FDA licences the once-monthly version of Lundbeck's blockbuster schizophrenia drug

Product updates from Japan

New approvals and filings include drugs from Takeda, Otsuka, Chugai and Astellas

- PMLiVE

TB vaccine disappoints, but others in the pipeline

Failure of first new vaccine in decades will guide development of others, say researchers

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links